Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860287 · ClinicalTrials.gov registry record · Early Phase 1
The Effects of Buprenorphine on Responses to Verbal Tasks
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
NCT01860287 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 48 participants.
The verdict
NCT01860287, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
In this study, the investigators will examine the effects of buprenorphine, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opioids and opiates in mediating social behavior in humans and other animals, and particularly, in social distress. Recently it has been shown that buprenorphine, a partial mu-opioid agonist, reduces sensitivity to recognition of fearful facial expressions in humans. Here, the investigators propose to further explore the role of the opioid system in mediating stress responses in humans through the use of buprenorphine. The investigators hypothesize that buprenorphine with reduce both physiological and subjective measures of stress.
Interventions
- DRUG Placebo
- DRUG Buprenorphine 0.2 MG Sublingual Tablet
- DRUG Buprenorphine 0.4 MG Sublingual Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01860287
The ClinicalTrials.gov registry entry for NCT01860287 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01860287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01860287 about?
NCT01860287 is a clinical study titled "The Effects of Buprenorphine on Responses to Verbal Tasks". In this study, the investigators will examine the effects of buprenorphine, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opio...
What is the current status of trial NCT01860287?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2013-09. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01860287?
The interventions under investigation include: Placebo (DRUG), Buprenorphine 0.2 MG Sublingual Tablet (DRUG), Buprenorphine 0.4 MG Sublingual Tablet (DRUG).
Who is sponsoring clinical trial NCT01860287?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.